JP2022153638A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022153638A5 JP2022153638A5 JP2022124557A JP2022124557A JP2022153638A5 JP 2022153638 A5 JP2022153638 A5 JP 2022153638A5 JP 2022124557 A JP2022124557 A JP 2022124557A JP 2022124557 A JP2022124557 A JP 2022124557A JP 2022153638 A5 JP2022153638 A5 JP 2022153638A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- bupropion
- disorders include
- humans
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002552 dosage form Substances 0.000 claims 23
- SNPPWIUOZRMYNY-VIFPVBQESA-N (S)-bupropion Chemical compound CC(C)(C)N[C@@H](C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-VIFPVBQESA-N 0.000 claims 7
- 208000015114 central nervous system disease Diseases 0.000 claims 6
- 241000282412 Homo Species 0.000 claims 5
- 229960001058 bupropion Drugs 0.000 claims 4
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 3
- RCOBKSKAZMVBHT-RNCFNFMXSA-N (2r,3r)-2-(3-chlorophenyl)-3,5,5-trimethylmorpholin-2-ol Chemical compound C[C@H]1NC(C)(C)CO[C@]1(O)C1=CC=CC(Cl)=C1 RCOBKSKAZMVBHT-RNCFNFMXSA-N 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 206010057852 Nicotine dependence Diseases 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634718P | 2018-02-23 | 2018-02-23 | |
| US62/634,718 | 2018-02-23 | ||
| US201962794469P | 2019-01-18 | 2019-01-18 | |
| US62/794,469 | 2019-01-18 | ||
| US201962809480P | 2019-02-22 | 2019-02-22 | |
| US62/809,480 | 2019-02-22 | ||
| JP2020544420A JP2021513998A (ja) | 2018-02-23 | 2019-02-25 | 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形 |
| PCT/US2019/019445 WO2019165379A1 (en) | 2018-02-23 | 2019-02-25 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544420A Division JP2021513998A (ja) | 2018-02-23 | 2019-02-25 | 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022153638A JP2022153638A (ja) | 2022-10-12 |
| JP2022153638A5 true JP2022153638A5 (enExample) | 2022-12-02 |
Family
ID=67688503
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544420A Pending JP2021513998A (ja) | 2018-02-23 | 2019-02-25 | 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形 |
| JP2022124557A Pending JP2022153638A (ja) | 2018-02-23 | 2022-08-04 | 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法 |
| JP2024041381A Pending JP2024075655A (ja) | 2018-02-23 | 2024-03-15 | 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544420A Pending JP2021513998A (ja) | 2018-02-23 | 2019-02-25 | 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024041381A Pending JP2024075655A (ja) | 2018-02-23 | 2024-03-15 | 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法 |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3755312A4 (enExample) |
| JP (3) | JP2021513998A (enExample) |
| KR (3) | KR20210003091A (enExample) |
| CN (2) | CN120827545A (enExample) |
| AU (3) | AU2019223187B2 (enExample) |
| BR (1) | BR112020017179A2 (enExample) |
| CA (1) | CA3092076A1 (enExample) |
| CL (1) | CL2020002166A1 (enExample) |
| CR (1) | CR20200415A (enExample) |
| EC (1) | ECSP20060179A (enExample) |
| IL (2) | IL276871B2 (enExample) |
| MA (1) | MA51914A (enExample) |
| MX (2) | MX2020008704A (enExample) |
| MY (1) | MY202993A (enExample) |
| NI (1) | NI202000056A (enExample) |
| NZ (1) | NZ767378A (enExample) |
| PE (1) | PE20211752A1 (enExample) |
| SG (1) | SG11202008056SA (enExample) |
| WO (1) | WO2019165379A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020008704A (es) * | 2018-02-23 | 2020-12-07 | Axsome Therapeutics Inc | Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro. |
| US11660273B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660274B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11291639B2 (en) | 2018-09-20 | 2022-04-05 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| CA3287347A1 (en) * | 2019-09-20 | 2025-11-29 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US12156914B2 (en) * | 2022-06-30 | 2024-12-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising bupropion and cysteine |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2483499A (en) * | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (+)-bupropion |
| US6337328B1 (en) * | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| SI1575565T1 (sl) * | 2003-08-08 | 2010-04-30 | Biovail Lab Int Srl | Tableta bupropion hidroklorida z modificiranim sprošŽŤanjem |
| WO2012118562A1 (en) * | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
| US9198905B2 (en) * | 2013-11-05 | 2015-12-01 | Antecip Bioventures Ii Llc | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
| US10080727B2 (en) * | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US9474731B1 (en) * | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US9732031B2 (en) * | 2013-12-20 | 2017-08-15 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
| MX2020008704A (es) * | 2018-02-23 | 2020-12-07 | Axsome Therapeutics Inc | Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro. |
-
2019
- 2019-02-25 MX MX2020008704A patent/MX2020008704A/es unknown
- 2019-02-25 AU AU2019223187A patent/AU2019223187B2/en active Active
- 2019-02-25 CR CR20200415A patent/CR20200415A/es unknown
- 2019-02-25 IL IL276871A patent/IL276871B2/en unknown
- 2019-02-25 MY MYPI2020004315A patent/MY202993A/en unknown
- 2019-02-25 WO PCT/US2019/019445 patent/WO2019165379A1/en not_active Ceased
- 2019-02-25 PE PE2020001272A patent/PE20211752A1/es unknown
- 2019-02-25 CN CN202510967625.3A patent/CN120827545A/zh active Pending
- 2019-02-25 SG SG11202008056SA patent/SG11202008056SA/en unknown
- 2019-02-25 CA CA3092076A patent/CA3092076A1/en active Pending
- 2019-02-25 KR KR1020207027256A patent/KR20210003091A/ko not_active Ceased
- 2019-02-25 JP JP2020544420A patent/JP2021513998A/ja active Pending
- 2019-02-25 KR KR1020237017449A patent/KR20230075531A/ko not_active Ceased
- 2019-02-25 IL IL313368A patent/IL313368A/en unknown
- 2019-02-25 KR KR1020247017593A patent/KR20240091043A/ko active Pending
- 2019-02-25 CN CN201980026874.5A patent/CN112087999A/zh active Pending
- 2019-02-25 MA MA051914A patent/MA51914A/fr unknown
- 2019-02-25 EP EP19756920.5A patent/EP3755312A4/en active Pending
- 2019-02-25 BR BR112020017179-4A patent/BR112020017179A2/pt unknown
- 2019-02-25 NZ NZ767378A patent/NZ767378A/en unknown
-
2020
- 2020-08-20 MX MX2023009281A patent/MX2023009281A/es unknown
- 2020-08-21 NI NI202000056A patent/NI202000056A/es unknown
- 2020-08-21 CL CL2020002166A patent/CL2020002166A1/es unknown
- 2020-09-23 EC ECSENADI202060179A patent/ECSP20060179A/es unknown
-
2022
- 2022-06-27 AU AU2022204521A patent/AU2022204521B2/en active Active
- 2022-08-04 JP JP2022124557A patent/JP2022153638A/ja active Pending
-
2024
- 2024-03-15 JP JP2024041381A patent/JP2024075655A/ja active Pending
- 2024-08-17 AU AU2024205858A patent/AU2024205858A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022153638A5 (enExample) | ||
| JP2023041862A5 (enExample) | ||
| JP2024075655A5 (ja) | 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用 | |
| AU2016256779B2 (en) | Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions | |
| JP2023171776A (ja) | 成人における焦点てんかんの処置のための合成経皮的カンナビジオール | |
| JP2002532392A5 (enExample) | ||
| JPWO1993011765A1 (ja) | （＋）アポビンカミン酸２−ニトロキシエチルエステルの新規な用途 | |
| JP2003503450A5 (enExample) | ||
| JP2006506378A5 (enExample) | ||
| JP2025020117A5 (enExample) | ||
| JP2018507243A5 (enExample) | ||
| JPH0269413A (ja) | アレルギー性鼻炎の治療方法 | |
| JP5842058B2 (ja) | 自閉症の治療における使用のためのクレンブテロール | |
| JP2023073373A5 (enExample) | ||
| JP2020522560A5 (enExample) | ||
| CN105025880A (zh) | 用于施用活性成分的盖仑氏形式 | |
| JP2016505050A5 (enExample) | ||
| JP2015529196A5 (enExample) | ||
| JP2020526575A5 (enExample) | ||
| JP2020503318A5 (enExample) | ||
| CN115607545A (zh) | 依达拉奉在自闭症谱系障碍治疗中的应用 | |
| JPWO2021089678A5 (enExample) | ||
| CN115835862A (zh) | 治疗阿尔茨海默病的组合及其应用 | |
| JPWO2020018291A5 (enExample) | ||
| JP2024059812A5 (ja) | 鏡像異性体的に濃縮された、または純粋なブプロピオンの組成物 |